

DengiAll

July 4, 2025 • vajiramandravi.com



DengiAll Latest News

India has reached the 50 per cent enrolment mark in its first phase III clinical trial for the indigenous tetravalent dengue vaccine, DengiAll.

About DengiAll

- It is developed by **Panacea Biotec Limited** under a licensing agreement with the **National Institutes of Health (NIH)**.
- has a weakened form of all four dengue virus subtypes and has the same virus composition as the vaccine developed by NIH, except for the inactive ingredients.
- A Phase I and II clinical trial conducted in India revealed a balanced and robust immune response across all four dengue virus types. The vaccine was also found to be safe and well-tolerated.
- Multiple ICMR institutes are involved in the study to evaluate the efficacy, immunogenicity and safety of DengiAll. The **ICMR-National Institute of Translational Virology (NITVAR)** and **AIDS Research** (formerly ICMR-NARI) is responsible for overall trial coordination.

Key Facts about Dengue

- It is a **mosquito-borne viral infection**.
- It is more common in **tropical and subtropical climates**, mostly in urban and semi-urban areas.

Transmission of Dengue

- It is transmitted to humans through the **bite of infected Aedes mosquitos** carrying one of four types of dengue virus (DENV).
- Dengue **isn't contagious from person to person** except when passed from a pregnant person to their child.

Symptoms of Dengue

- The most common symptoms are high fever, headache, body aches, nausea, and rash. Most will get better in 1–2 weeks.
- A very small portion of people with dengue fever get a severe case. It's called dengue hemorrhagic fever.
- **Treatment:** There is **no specific medicine to treat dengue**. The focus is on treating pain symptoms.

Source: **IE**

Source: <https://vajiramandravi.com/current-affairs/dengiall/>

© Vajiram & Ravi. For personal use only.